Recipharm to produce H. pylori drug for RedHill Biopharma

Swedish contract development and manufacturing company Recipharm has signed an agreement with Israeli biotech firm RedHill Biopharma (TASE: RDHL) for the manufacturing of RedHill’s leading, late-stage patented drug candidate, RHB-105.

RHB-105 is being developed for the treatment of Helicobacter pylori bacterial infection, a global market estimated at about $4.8 billion and $1.45 billion in the USA. Recipharm will be responsible for the supply of the remaining clinical trial material and ongoing future commercial supply.

RHB-105 is a new and proprietary fixed-dose oral combination therapy of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole) combined into an all-in-one oral capsule with a planned indication for treatment of H. pylori infection. Earlier this year, RHB-105 successfully met its primary endpoint in its first Phase III study (The Pharma Letter June 15).